 |
 Video: What is a Stock Split?
|
|
|
| Lixte Biotechnology Holdings is a drug discovery company that uses biomarker technology to identify enzyme targets associated with diseases and then designs compounds to attack those targets. Co.'s product pipeline is focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers. Co. is developing two classes of drugs for the treatment of cancer, consisting of protein phosphatase inhibitors, designated by Co. as the LB-100 series of compounds, and histone deacetylase inhibitors, designated by Co. as the LB-200 series of compounds. Co.'s focus is on the clinical development of the LB-100 series of compounds. According to our LIXT split history records, Lixte Biotechnology Holdings has had 1 split. | |
|
Lixte Biotechnology Holdings (LIXT) has 1 split in our LIXT split history database. The split for LIXT took place on June 05, 2023. This was a 1 for 10 reverse split, meaning for each 10 shares of LIXT owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.
When a company such as Lixte Biotechnology Holdings conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the LIXT split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Lixte Biotechnology Holdings shares, starting with a $10,000 purchase of LIXT, presented on a split-history-adjusted basis factoring in the complete LIXT split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/29/2014 |
|
| End date: |
04/26/2024 |
|
| Start price/share: |
$2.50 |
|
| End price/share: |
$3.26 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
30.40% |
|
| Average Annual Total Return: |
2.69% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$13,040.12 |
|
| Years: |
10.00 |
|
|
|
| Date |
Ratio |
| 06/05/2023 | 1 for 10 |
|
|
Free LIXT Email Alerts:
